Centene (CNC)
(Delayed Data from NYSE)
$78.09 USD
+0.18 (0.23%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $78.06 -0.03 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum A VGM
Centene (CNC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$83.94 | $95.00 | $74.00 | 7.74% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Centene comes to $83.94. The forecasts range from a low of $74.00 to a high of $95.00. The average price target represents an increase of 7.74% from the last closing price of $77.91.
Analyst Price Targets (16)
Broker Rating
Centene currently has an average brokerage recommendation (ABR) of 2.11 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, eight are Strong Buy, representing 44.44% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CNC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 10 | 10 | 9 | 9 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.11 | 2.11 | 2.00 | 2.00 | 1.94 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/24/2024 | Not Identified | Not Identified | Strong Buy | Hold |
7/23/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
7/22/2024 | Wells Fargo Securities | Stephen Baxter | Strong Buy | Strong Buy |
6/18/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Hold | Hold |
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Hold |
4/15/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
4/8/2024 | Not Identified | Not Identified | Hold | Hold |
3/21/2024 | Stephens | Scott Fidel | Strong Buy | Hold |
3/6/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
12/31/2023 | Goldman Sachs | Nathan Rich | Hold | Hold |
12/21/2023 | UBS | Kevin Caliendo | Hold | Hold |
12/1/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
10/24/2023 | Argus Research Corp. | John D Staszak | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.11 |
ABR (Last week) | 2.11 |
# of Recs in ABR | 18 |
Average Target Price | $83.94 |
LT Growth Rate | 11.40% |
Industry | Medical - HMOs |
Industry Rank by ABR | 78 of 253 |
Current Quarter EPS Est: | 1.77 |